FDA gives Baltimore firm’s drug ‘orphaned’ status

Gliknik Inc., a privately held biopharmaceutical company based in Baltimore, on Monday announced the FDA granted its autoimmune candidate drug GL-2045 orphan drug designation for Chronic Inflammatory Demyelinating Polyneuropathy, a rare neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms. The FDA Office of Orphan Products Development grants orphan drug ...

Leave a Reply

Your email address will not be published. Required fields are marked *